際際滷

際際滷Share a Scribd company logo
TREATMENT
   OF
 LEPROSY

Susana V. Caseria, MD
What is MDT?
 Multi-Drug Therapy (MDT) is the
  accepted standard treatment for
  leprosy.
 It is a combination of two (2) or
  more anti-leprosy drugs:
   Dapsone            Ofloxacin
   Rifampicin         Minocycline
   Clofazimine
PB Blister Pack   PB Blister Pack
    (Adult)           (Child)
MB Blister Pack   MB Blister Pack
   (Adult)           (Child)
SIDE EFFECTS:

Rifampicin:
 May cause slightly reddish discoloration
  of urine within a few hours after intake.
 Patient may experience body malaise,
  joint and muscle pains.
SIDE EFFECTS:

Clofazimine:
 Gastric irritation.
 Skin discoloration
  (disappears a few months
  after stopping treatment).
SIDE EFFECTS:

Clofazimine:
 Gastric irritation.
 Skin discoloration
  (disappears a few months
  after stopping treatment).
 Dryness of skin.
SIDE EFFECTS:

Dapsone:
 Side effects are rare.
 Some patients may develop allergic
  reactions causing itchy skin rashes and
  exfoliative dermatitis.
 Patients who are allergic to any of the
  sulfa drugs should not be given Dapsone.
SIDE EFFECTS
DAPSONE
  Hemolytic anemia  most common
             G6PD deficiency
  Psychosis
  DDS Syndrome - 1st 6 weeks
     Fever
     Exfoliative dermatitis
     Hepatitis
     Cholestatic jaundice
      splenomegaly
     lymphadenopathy
FLUOROQUINOLONES
   Inhibit DNA gyrase
   Basically vs. gram (-) bacteria
   In vivo & in vitro activity of Ofloxacin against M.leprae (Saito,et
    al, 1986)
   3 commercial derivatives tested in mouse footpad system
                           (Grosset, et al)
          -Ciprofloxacin was inactive
          -Pefloxacin had bactericidal activity at
                                 150mg/KBNW/day
          -Ofloxacin at 50 mg/KBW/day had the same effect
          -Ofloxacin at 1500 mg/KBW/day had profound killing
                               activity
SIDE EFFECTS:

Ofloxacin:
 Well absorbed, reaches peak serum
  concentration after 2 hours.
 May cause nausea, diarrhea, headache,
  dizziness and insomnia.
MINOCYCLINE
   Activity of minocycline in M. leprae infected
    mice ( Dr. Gelber, 1987)
   Clinical trial of minocycline in lepromatous
    leprosy (Dr. Gelber et al)
        - 8 untreated lepromatous pts
        - 100 OD X 3 mos.
        - all were negative after 3 months
        - clearance :faster than dapsone &,
          clofazimine, slower than rifampicin &
          similar to pefloxacin, ofloxacin
SIDE EFFECTS:

Minocycline:
 Has significant bactericidal activity
  against M. leprae.
 May cause discoloration of teeth in
  children, occasional pigmentation of the
  skin, gastro-intestinal disturbance and
  dizziness.
CONTRA-INDICATIONS TO MDT:
 Cases with severe liver and kidney
  disease.
 Severe hypersensitivity to any of the
  MDT drugs.
 Severe anemia.
 Ofloxacin & Minocycline are not
  recommended for use in pregnant women
  and children below five (5) years old.
TREATMENT: MULTIBACILLARY
        LEPROSY
   TRIPLE DRUG THERAPY
      1. Dapsone 100 mg OD
      2. Clofazimine 50 mg OD

AND Supervised
   3. Rifampicin 600 mg monthly
   4. Clofazimine 300 mg monthly
TREATMENT: PAUCIBACILLARY
        LEPROSY
   DUAL DRUG THERAPY
      1. Dapsone 100 mg OD

AND Supervised
   2. Rifampicin 600 mg monthly
DURATION OF TREATMENT

   MULTIBACILLARY: 12 months

   PAUCIBACILLARY: 6 months
Adult Multibacillary Regimen:
(For MB leprosy patients above 15 years old)

                Day 1              Rifampicin  600mg
                (Monthly Dose)     Clofazimine  300mg
                                   Dapsone  100mg
                Day 2-28           Clofazimine  50mg
                (Daily Doses)      Dapsone  100mg

                Duration of        Twelve (12) blister
                Treatment          packs to be taken
                                   monthly within a
                                   maximum of 18
                                   months
Pedia Multibacillary Regimen:
(For MB leprosy patients 10-15 years old)

                Day 1              Rifampicin  450mg
                (Monthly Dose)     Clofazimine  150mg
                                   Dapsone  50mg
                Day 2-28           Clofazimine  50mg
                (Daily Doses)      (every other day)
                                   Dapsone  50mg
                Duration of        Twelve (12) blister
                Treatment          packs to be taken
                                   monthly within a
                                   maximum of 18
                                   months
Adult Paucibacillary Regimen:
(For PB leprosy patients above 15 years old)

                Day 1               Rifampicin  600mg
                (Monthly Dose)      Dapsone  100mg
                Day 2-28            Dapsone  100mg
                (Daily Doses)
                Duration of         Six (6) blister packs
                Treatment           to be taken monthly
                                    within a maximum
                                    of nine (9) months
Pedia Paucibacillary Regimen:
(For PB leprosy patients 10-15 years old)

                Day 1               Rifampicin  450mg
                (Monthly Dose)      Dapsone  50mg
                Day 2-28            Dapsone  50mg
                (Daily Doses)
                Duration of         Six (6) blister packs
                Treatment           to be taken monthly
                                    within a maximum
                                    of nine (9) months
For children below ten
(10) years old, the dose
may be adjusted.
                           i
Single-Lesion Paucibacillary Regimen:
(ROM for SLPB leprosy patients)

                        Adult (2 blister packs)
                Rifampicin  600mg (2 x 300mg)
                Ofloxacin  400mg (2 x 200mg)
                Minocycline  100mg (2 x 50mg)

                        Child (1 blister pack)
                Rifampicin  300mg
                Ofloxacin  200mg
                Minocycline  50mg
TREATMENT

   Leprosy can now be treated at home
   Health Education is an integral part of
    treatment
   To be effective, treatment should be
    adequate, regular and continuous
TREAT CORRECTLY THEN STOP
        TREATMENT
   Always treat with full doses

   Never reduce the dose

   If complications arise, may use a different
    drug
THE MAJOR PROBLEM IN
       LEPROSY CONTROL
              IS
PATIENT COMPLIANCE
 Use every means to gain patients
 cooperation, so that they will take
 treatment as long as necessary
4. treatment
4. treatment
PATIENT EDUCATION:
    The success of MDT treatment is the
joint responsibility of the doctor and the
leprosy patient.
    Please educate your patient about the
importance of treatment compliance and give
corresponding instructions or advice.
4. treatment
Important Messages
                              Health Advice / Instruction
      About MDT
1. Leprosy is curable with          Advise the patient to
   MDT if taken regularly     take his monthly and daily
   and continuously, and if   doses of MDT drugs
   the prescribed number      regularly, continuously
   of blister packs are       and adequately to make
   consumed within the        sure that he gets cured of
   prescribed period of 12-   the disease.
   18 months for MB and
   6-9 months for PB.
Important Messages
                            Health Advice / Instruction
      About MDT
2. A leprosy patient              Explain to the patient
   becomes non-infectious   and his family that he
   after starting MDT.      becomes non-infectious
                            one month after taking the
                            initial dose of MDT drugs.
Important Messages
                          Health Advice / Instruction
      About MDT
3. During the course of         Teach the patient to
   treatment, leprosy     recognize the early signs
   reactions may occur.   of reaction and advise him
                          to report immediately for
                          appropriate intervention in
                          case it occurs.
                               Advise him to
                          continue MDT intake
                          even during reactions.
Important Messages
                              Health Advice / Instruction
      About MDT
4. Impairments of the eyes,         Advise the patient to
   hands and feet are         take care of his anesthetic
   preventable.               eyes, hands and feet by
                              using protective devices
                              such as sunglasses, hats,
                              gloves and shoes.
Important Messages
                           Health Advice / Instruction
      About MDT
5. MDT is available FREE         Advise the patient to
   of charge in Rural      collect his MDT blister
   Health Units.           packs at the RHU until all
                           the prescribed number of
                           blister packs are taken.
TREATMENT COMPLETION:
Treatment is completed when:
 A PB patient has taken 6 MDT blister
  packs within 6-9 months.
 An MB patient has taken 12 MDT blister
  packs within 12-18 months.
 An SLPB patient has taken the single
  dose of ROM.
Remember: A leprosy
case who has completed a
full course of treatment
                             i
should no longer be regarded as a
leprosy patient.
TREATMENT COMPLETION:
Upon completion of treatment:
 Remind the patient about the early signs
  of a leprosy reaction.
 Teach him the early signs of a relapse.
 Encourage him to continue self-care of
  the eyes, hands and feet to prevent
  injuries that may lead to deformities.
DEFAULTERS:
     A defaulter is a patient who has started
treatment but who has not collected his
MDT drugs for six (6) consecutive months.
     It is, however, important that adequate
efforts are made to trace these patients and
persuade them to return for assessment and
re-treatment.
A defaulter who returns
for re-treatment should
be given a new course of
                           i
MDT.
PATIENTS WITH SPECIAL NEEDS:
Accompanied MDT:
    Sometimes, patients have to interrupt
their treatment for one reason or another:
 Poor access to the health service;
 No one is at the Health Center when they
   come to collect their blister packs;
 Nature of work (e.g. fisherman);
 Insurgency.
PATIENTS WITH SPECIAL NEEDS:
Accompanied MDT:
     With Accompanied MDT, they are given
the first dose at the Health Center, and
allowed to bring home the remaining blister
packs to complete the treatment at home.
PATIENTS WITH SPECIAL NEEDS:
Accompanied MDT:
     The treatment procedure is taught to the
patient and, if possible, a home companion.
They are then instructed to report to the
Health Center if problems occur or when
treatment is completed.
PATIENTS WITH SPECIAL NEEDS:
Pregnancy:
     The standard regimens are considered
safe for both the mother and child.
     If a woman becomes pregnant during the
course of treatment, continue MDT.
     However, if a woman is 1-3 months
pregnant, wait until the 2nd trimester before
starting MDT.
PATIENTS WITH SPECIAL NEEDS:
Tuberculosis:
    Patients suffering from both leprosy and
tuberculosis require appropriate anti-TB
therapy in addition to MDT.
PATIENTS WITH SPECIAL NEEDS:
Tuberculosis:
    Since Rifampicin doses for TB are larger
than those in MDT, remove the Rifampicin
capsules from the MDT blister packs for the
duration of the TB therapy.
    Give the Clofazimine and Dapsone
together with the TB regimen.
    When the TB treatment is completed,
resume the prescribed MDT regimen.
PATIENTS WITH SPECIAL NEEDS:
HIV Infection:
    The management of a leprosy patient
infected with HIV is the same as with any
other leprosy patient.
    Information available so far indicate that
their response to MDT is the same.
    The management, including treatment of
reactions, does not require modifications.
PATIENTS WITH SPECIAL NEEDS:
Relapse:
    Relapse is the recurrence of leprosy after
the successful completion of treatment.
   It is characterized by the occurrence of
new lesions.
PATIENTS WITH SPECIAL NEEDS:
Relapse:
    The probability of relapse after MDT is
very rare.
    It is often confused with reactions which
can also occur after cure.
    A Morphological Index is highly
recommended when there is suspicion of a
relapse.
OTHER POSSIBLE DRUGS
   CLARITHROMYCIN
   BETA LACTAM ANTIBIOTIC
   RIFAMYCIN DERIVATIVES
   STREPTOMYCIN
   FUSIDIC ACID
CLARITHROMYCIN
   Completely prevented the growth of M.
    leprae resistant & susceptible to dapsone
    & rifampicin (Walker,et al)
   No antagonistic drug interaction with
    rifampicin
   Less active than minocycline (Ji, et al)
   Minocycline and clarithromycin have
    additive effects
OTHER DRUGS
   Beta Lactam antibiotic
       -interfere with cell wall synthwesis
       -must be administered by injection
   Rifamycin derivatives
       -Rifabutin, Rifapertine, and R-76-1
       -No difference in activity with
          Rifampicin
       -No report to support activity vs.
         rifampicin-resistant strains
OTHER DRUGS

STREPTOMYCIN
   -Bacteriostatic
   -Given by injection

FUSIDIC ACID
    -Highly active against intra/extracellular
 M. leprae (Franzblau, et al)
Thank You!

More Related Content

4. treatment

  • 1. TREATMENT OF LEPROSY Susana V. Caseria, MD
  • 2. What is MDT? Multi-Drug Therapy (MDT) is the accepted standard treatment for leprosy. It is a combination of two (2) or more anti-leprosy drugs: Dapsone Ofloxacin Rifampicin Minocycline Clofazimine
  • 3. PB Blister Pack PB Blister Pack (Adult) (Child)
  • 4. MB Blister Pack MB Blister Pack (Adult) (Child)
  • 5. SIDE EFFECTS: Rifampicin: May cause slightly reddish discoloration of urine within a few hours after intake. Patient may experience body malaise, joint and muscle pains.
  • 6. SIDE EFFECTS: Clofazimine: Gastric irritation. Skin discoloration (disappears a few months after stopping treatment).
  • 7. SIDE EFFECTS: Clofazimine: Gastric irritation. Skin discoloration (disappears a few months after stopping treatment). Dryness of skin.
  • 8. SIDE EFFECTS: Dapsone: Side effects are rare. Some patients may develop allergic reactions causing itchy skin rashes and exfoliative dermatitis. Patients who are allergic to any of the sulfa drugs should not be given Dapsone.
  • 9. SIDE EFFECTS DAPSONE Hemolytic anemia most common G6PD deficiency Psychosis DDS Syndrome - 1st 6 weeks Fever Exfoliative dermatitis Hepatitis Cholestatic jaundice splenomegaly lymphadenopathy
  • 10. FLUOROQUINOLONES Inhibit DNA gyrase Basically vs. gram (-) bacteria In vivo & in vitro activity of Ofloxacin against M.leprae (Saito,et al, 1986) 3 commercial derivatives tested in mouse footpad system (Grosset, et al) -Ciprofloxacin was inactive -Pefloxacin had bactericidal activity at 150mg/KBNW/day -Ofloxacin at 50 mg/KBW/day had the same effect -Ofloxacin at 1500 mg/KBW/day had profound killing activity
  • 11. SIDE EFFECTS: Ofloxacin: Well absorbed, reaches peak serum concentration after 2 hours. May cause nausea, diarrhea, headache, dizziness and insomnia.
  • 12. MINOCYCLINE Activity of minocycline in M. leprae infected mice ( Dr. Gelber, 1987) Clinical trial of minocycline in lepromatous leprosy (Dr. Gelber et al) - 8 untreated lepromatous pts - 100 OD X 3 mos. - all were negative after 3 months - clearance :faster than dapsone &, clofazimine, slower than rifampicin & similar to pefloxacin, ofloxacin
  • 13. SIDE EFFECTS: Minocycline: Has significant bactericidal activity against M. leprae. May cause discoloration of teeth in children, occasional pigmentation of the skin, gastro-intestinal disturbance and dizziness.
  • 14. CONTRA-INDICATIONS TO MDT: Cases with severe liver and kidney disease. Severe hypersensitivity to any of the MDT drugs. Severe anemia. Ofloxacin & Minocycline are not recommended for use in pregnant women and children below five (5) years old.
  • 15. TREATMENT: MULTIBACILLARY LEPROSY TRIPLE DRUG THERAPY 1. Dapsone 100 mg OD 2. Clofazimine 50 mg OD AND Supervised 3. Rifampicin 600 mg monthly 4. Clofazimine 300 mg monthly
  • 16. TREATMENT: PAUCIBACILLARY LEPROSY DUAL DRUG THERAPY 1. Dapsone 100 mg OD AND Supervised 2. Rifampicin 600 mg monthly
  • 17. DURATION OF TREATMENT MULTIBACILLARY: 12 months PAUCIBACILLARY: 6 months
  • 18. Adult Multibacillary Regimen: (For MB leprosy patients above 15 years old) Day 1 Rifampicin 600mg (Monthly Dose) Clofazimine 300mg Dapsone 100mg Day 2-28 Clofazimine 50mg (Daily Doses) Dapsone 100mg Duration of Twelve (12) blister Treatment packs to be taken monthly within a maximum of 18 months
  • 19. Pedia Multibacillary Regimen: (For MB leprosy patients 10-15 years old) Day 1 Rifampicin 450mg (Monthly Dose) Clofazimine 150mg Dapsone 50mg Day 2-28 Clofazimine 50mg (Daily Doses) (every other day) Dapsone 50mg Duration of Twelve (12) blister Treatment packs to be taken monthly within a maximum of 18 months
  • 20. Adult Paucibacillary Regimen: (For PB leprosy patients above 15 years old) Day 1 Rifampicin 600mg (Monthly Dose) Dapsone 100mg Day 2-28 Dapsone 100mg (Daily Doses) Duration of Six (6) blister packs Treatment to be taken monthly within a maximum of nine (9) months
  • 21. Pedia Paucibacillary Regimen: (For PB leprosy patients 10-15 years old) Day 1 Rifampicin 450mg (Monthly Dose) Dapsone 50mg Day 2-28 Dapsone 50mg (Daily Doses) Duration of Six (6) blister packs Treatment to be taken monthly within a maximum of nine (9) months
  • 22. For children below ten (10) years old, the dose may be adjusted. i
  • 23. Single-Lesion Paucibacillary Regimen: (ROM for SLPB leprosy patients) Adult (2 blister packs) Rifampicin 600mg (2 x 300mg) Ofloxacin 400mg (2 x 200mg) Minocycline 100mg (2 x 50mg) Child (1 blister pack) Rifampicin 300mg Ofloxacin 200mg Minocycline 50mg
  • 24. TREATMENT Leprosy can now be treated at home Health Education is an integral part of treatment To be effective, treatment should be adequate, regular and continuous
  • 25. TREAT CORRECTLY THEN STOP TREATMENT Always treat with full doses Never reduce the dose If complications arise, may use a different drug
  • 26. THE MAJOR PROBLEM IN LEPROSY CONTROL IS PATIENT COMPLIANCE Use every means to gain patients cooperation, so that they will take treatment as long as necessary
  • 29. PATIENT EDUCATION: The success of MDT treatment is the joint responsibility of the doctor and the leprosy patient. Please educate your patient about the importance of treatment compliance and give corresponding instructions or advice.
  • 31. Important Messages Health Advice / Instruction About MDT 1. Leprosy is curable with Advise the patient to MDT if taken regularly take his monthly and daily and continuously, and if doses of MDT drugs the prescribed number regularly, continuously of blister packs are and adequately to make consumed within the sure that he gets cured of prescribed period of 12- the disease. 18 months for MB and 6-9 months for PB.
  • 32. Important Messages Health Advice / Instruction About MDT 2. A leprosy patient Explain to the patient becomes non-infectious and his family that he after starting MDT. becomes non-infectious one month after taking the initial dose of MDT drugs.
  • 33. Important Messages Health Advice / Instruction About MDT 3. During the course of Teach the patient to treatment, leprosy recognize the early signs reactions may occur. of reaction and advise him to report immediately for appropriate intervention in case it occurs. Advise him to continue MDT intake even during reactions.
  • 34. Important Messages Health Advice / Instruction About MDT 4. Impairments of the eyes, Advise the patient to hands and feet are take care of his anesthetic preventable. eyes, hands and feet by using protective devices such as sunglasses, hats, gloves and shoes.
  • 35. Important Messages Health Advice / Instruction About MDT 5. MDT is available FREE Advise the patient to of charge in Rural collect his MDT blister Health Units. packs at the RHU until all the prescribed number of blister packs are taken.
  • 36. TREATMENT COMPLETION: Treatment is completed when: A PB patient has taken 6 MDT blister packs within 6-9 months. An MB patient has taken 12 MDT blister packs within 12-18 months. An SLPB patient has taken the single dose of ROM.
  • 37. Remember: A leprosy case who has completed a full course of treatment i should no longer be regarded as a leprosy patient.
  • 38. TREATMENT COMPLETION: Upon completion of treatment: Remind the patient about the early signs of a leprosy reaction. Teach him the early signs of a relapse. Encourage him to continue self-care of the eyes, hands and feet to prevent injuries that may lead to deformities.
  • 39. DEFAULTERS: A defaulter is a patient who has started treatment but who has not collected his MDT drugs for six (6) consecutive months. It is, however, important that adequate efforts are made to trace these patients and persuade them to return for assessment and re-treatment.
  • 40. A defaulter who returns for re-treatment should be given a new course of i MDT.
  • 41. PATIENTS WITH SPECIAL NEEDS: Accompanied MDT: Sometimes, patients have to interrupt their treatment for one reason or another: Poor access to the health service; No one is at the Health Center when they come to collect their blister packs; Nature of work (e.g. fisherman); Insurgency.
  • 42. PATIENTS WITH SPECIAL NEEDS: Accompanied MDT: With Accompanied MDT, they are given the first dose at the Health Center, and allowed to bring home the remaining blister packs to complete the treatment at home.
  • 43. PATIENTS WITH SPECIAL NEEDS: Accompanied MDT: The treatment procedure is taught to the patient and, if possible, a home companion. They are then instructed to report to the Health Center if problems occur or when treatment is completed.
  • 44. PATIENTS WITH SPECIAL NEEDS: Pregnancy: The standard regimens are considered safe for both the mother and child. If a woman becomes pregnant during the course of treatment, continue MDT. However, if a woman is 1-3 months pregnant, wait until the 2nd trimester before starting MDT.
  • 45. PATIENTS WITH SPECIAL NEEDS: Tuberculosis: Patients suffering from both leprosy and tuberculosis require appropriate anti-TB therapy in addition to MDT.
  • 46. PATIENTS WITH SPECIAL NEEDS: Tuberculosis: Since Rifampicin doses for TB are larger than those in MDT, remove the Rifampicin capsules from the MDT blister packs for the duration of the TB therapy. Give the Clofazimine and Dapsone together with the TB regimen. When the TB treatment is completed, resume the prescribed MDT regimen.
  • 47. PATIENTS WITH SPECIAL NEEDS: HIV Infection: The management of a leprosy patient infected with HIV is the same as with any other leprosy patient. Information available so far indicate that their response to MDT is the same. The management, including treatment of reactions, does not require modifications.
  • 48. PATIENTS WITH SPECIAL NEEDS: Relapse: Relapse is the recurrence of leprosy after the successful completion of treatment. It is characterized by the occurrence of new lesions.
  • 49. PATIENTS WITH SPECIAL NEEDS: Relapse: The probability of relapse after MDT is very rare. It is often confused with reactions which can also occur after cure. A Morphological Index is highly recommended when there is suspicion of a relapse.
  • 50. OTHER POSSIBLE DRUGS CLARITHROMYCIN BETA LACTAM ANTIBIOTIC RIFAMYCIN DERIVATIVES STREPTOMYCIN FUSIDIC ACID
  • 51. CLARITHROMYCIN Completely prevented the growth of M. leprae resistant & susceptible to dapsone & rifampicin (Walker,et al) No antagonistic drug interaction with rifampicin Less active than minocycline (Ji, et al) Minocycline and clarithromycin have additive effects
  • 52. OTHER DRUGS Beta Lactam antibiotic -interfere with cell wall synthwesis -must be administered by injection Rifamycin derivatives -Rifabutin, Rifapertine, and R-76-1 -No difference in activity with Rifampicin -No report to support activity vs. rifampicin-resistant strains
  • 53. OTHER DRUGS STREPTOMYCIN -Bacteriostatic -Given by injection FUSIDIC ACID -Highly active against intra/extracellular M. leprae (Franzblau, et al)